Pancreatic cancer has resisted everything for decades — a new kind of drug is finally getting through

Pancreatic cancer is notorious for shrugging off treatment. Oncologists at the University of Texas Medical Branch say a newly approved drug, daraxonrasib, represents a different approach: it targets the RAS pathway, a growth switch that drives most pancreatic tumours and was long considered undruggable. It is one of several targeted therapies now giving doctors new ways to attack the disease — and patients a reason for renewed, careful hope.